

Ignyta, Inc.  
Form 8-K  
April 08, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 8, 2016**

**IGNYTA, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
**(State of**  
  
**Incorporation)**

**001-36344**  
**(Commission**  
  
**File Number)**  
**11111 Flintkote Avenue**

**45-3174872**  
**(IRS Employer**  
  
**Identification No.)**

Edgar Filing: Ignyta, Inc. - Form 8-K

**San Diego, California 92121**

**(Address of principal executive offices, including zip code)**

**Registrant's telephone number, including area code: (858) 255-5959**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.02 Termination of a Material Definitive Agreement**

Effective as of April 8, 2016, Ignyta, Inc. (the Company ) and Cancer Research Technology Limited ( CRT ) mutually agreed to terminate the License Agreement between the Company and CRT dated as of January 20, 2014 (the CRT Agreement ). The termination of the CRT Agreement was due to the Company s prior determination to cease all development activities relating to its RXDX-108 program.

The parties have agreed to cooperate in an orderly transition of the RXDX-108 program and related information and assets to CRT, including all related intellectual property rights. The Company does not expect to incur any material expenses in connection with the termination of the CRT Agreement.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 8, 2016

**IGNYTA, INC.**

By: /s/ Jonathan E. Lim, M.D.

Name: Jonathan E. Lim, M.D.

Title: President and Chief Executive Officer